Sol-Gel Technologies (SLGL) Profit After Tax (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Profit After Tax of $1.31 for Q1 2026, down 59.06% year-over-year from $3.2 in Q1 2025, and up 100.0% quarter-over-quarter from -$9.3 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Profit After Tax (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Profit After Tax for 10 consecutive years, with $1.31 the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 59.06% year-over-year to $1.31; the TTM figure through Mar 2026 stood at $8.3 million (up 160.46% YoY), while the FY2025 annual figure was -$6.1 million, up 42.09% from the prior year.
- Profit After Tax grew to $1.31 in Q1 2026 per SLGL's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $11.6 million in Q2 2025 and bottomed at -$15.3 million in Q4 2024.
- Historically, Profit After Tax has averaged -$793940.7 across 5 years, with a median of $0.43 in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 59699999900.0% — and 2024, when it slumped 216.67%.
- Sol-Gel Technologies' Profit After Tax stood at -$14.9 million in 2022, then surged by 67.59% to -$4.8 million in 2023, then plunged by 216.67% to -$15.3 million in 2024, then jumped by 39.49% to -$9.3 million in 2025, then jumped by 100.0% to $1.31 in 2026.
- Business Quant data shows SLGL's Profit After Tax at $1.31 in Q1 2026, -$9.3 million in Q4 2025, and $5.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 3.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.68 Mn |
| Mar 31, 2026 | 3.73 Mn |
| Dec 31, 2025 | 9.27 Mn |
| Sep 30, 2025 | -5.94 Mn |
| Jun 30, 2025 | 11.61 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | 15.31 Mn |
| Sep 30, 2024 | -366,000.00 |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 6.34 Mn |
| Dec 31, 2023 | 49.64 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -5.97 Mn |
| Mar 31, 2023 | 10.72 Mn |
| Dec 31, 2022 | 24.06 Mn |
| Sep 30, 2022 | -3.41 Mn |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 5.60 Mn |
| Dec 31, 2021 | 14.03 Mn |
| Sep 30, 2021 | 1.29 Mn |